FDA approves Regeneron's gene therapy for inherited deafness
23/04/2026 17:42
April 23 (Reuters) - U.S. Food and Drug Administration has approved Regeneron's REGN.O gene therapy for a rare genetic form of deafness, the company said on Thursday. (Reporting by Sriparna Roy in Bengaluru; Editing by Vijay Kishore) ((Sriparna.Roy@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement